Compare VREX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VREX | MYGN |
|---|---|---|
| Founded | 2016 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.9M | 444.2M |
| IPO Year | 2016 | 1996 |
| Metric | VREX | MYGN |
|---|---|---|
| Price | $10.35 | $5.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $16.67 | $7.64 |
| AVG Volume (30 Days) | 335.8K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $811,000,000.00 | $771,400,000.00 |
| Revenue This Year | $5.35 | $6.86 |
| Revenue Next Year | $3.88 | $5.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $6.76 | $3.53 |
| 52 Week High | $14.57 | $8.59 |
| Indicator | VREX | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 69.85 |
| Support Level | $10.18 | $4.24 |
| Resistance Level | $12.60 | $5.52 |
| Average True Range (ATR) | 0.52 | 0.30 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 25.84 | 92.02 |
Varex Imaging Corp Designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, detectors, ionization chambers, high-voltage connectors, software, collimators, generators, exposure control devices, and heat exchangers.. The company operates through two segments: Medical, the key revenue driver, providing X-ray imaging components and accessories for healthcare applications, and Industrial, which provides Linatron X-ray accelerators, X-ray tubes, flat panel detectors, high-voltage connectors, and coolers for non-medical use. Geographically, it generates the majority of its revenue from Europe, the Middle East, and Africa (EMEA), with the rest coming from the Americas and Asia Pacific.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.